In conclusion, we report potent anti-tumor activity of monospecific anti-TACI and bispecific anti-BCMA–anti-TACI CAR T cells in vitro and in xenograft models of multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.